Olema partners with Bayer for OP-3136 + darolutamide Phase 1b/2 in mCRPC; 36 patients, H2 2026 start

Olema Pharmaceuticals, Inc.

Olema and Bayer will evaluate OP-3136 (KAT6 inhibitor) combined with darolutamide in ~36 mCRPC patients.
Phase 1b/2 study expected to initiate in second half of 2026; Bayer supplies darolutamide.
Olema retains full global commercial and marketing rights to OP-3136; clinical data and inventions jointly owned.
First clinical collaboration for OP-3136; builds on ongoing Phase 1/2 monotherapy and combination studies.
Olema to present initial Phase 1 OP-3136 monotherapy data at ASCO on May 30, 2026.

item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-237832
form_type: 8-K
ticker: OLMA
cik: 0001750284
company_name: Olema Pharmaceuticals, Inc.
filed_at: 2026-05-26T11:05:16+00:00
discovered_at: 2026-05-26T11:10:00.237897+00:00
generated_at: 2026-05-26T11:14:23.093292+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.55
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-237832
json_url: https://secwatch.observer/filing/0001193125-26-237832.json
markdown_url: https://secwatch.observer/filing/0001193125-26-237832.md
text_url: https://secwatch.observer/filing/0001193125-26-237832.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1750284/000119312526237832/0001193125-26-237832-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1750284/000119312526237832/olma-20260526.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-237832

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.